2023. Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s114. DOI:https://doi.org/10.25251/skin.7.supp.114.